Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edaravone - Mitsubishi Tanabe Pharma

Next Previous
Drug Profile

Edaravone - Mitsubishi Tanabe Pharma

Alternative Names: 1-phenyl-3-methyl-5-pyrazolone; Edarabone; MCI-186; MT 1186; Norphenazone; Phenylmethylpyrazolone; RADICAVA; Radicava; RADICAVA ORS; RADICUT; Radicut; Radicut Bag

Latest Information Update: 10 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Canada; Mitsubishi Tanabe Pharma Corporation
  • Class Anti-ischaemics; Antidementias; Antihaemorrhagics; Antiparkinsonians; Hepatoprotectants; Neuroprotectants; Pyrazolones; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyotrophic lateral sclerosis; Cerebral infarction
  • Phase II Stroke
  • No development reported Liver disorders
  • Discontinued Myocardial ischaemia; Parkinson's disease; Reperfusion injury; Subarachnoid haemorrhage

Most Recent Events

  • 07 Nov 2023 Edaravone has been added to the Provincial Drug Plans in Prince Edward Island, Newfoundland and Labrador
  • 08 Aug 2023 Mitsubishi Tanabe Pharma completes a phase III trial for Amyotrophic lateral sclerosis in Canada, France, Germany, Italy, Japan, USA (PO) (NCT04577404)
  • 31 Jul 2023 Mitsubishi Tanabe Pharma Corporation terminates a phase-III trial in Amyotrophic lateral sclerosis in US, Canada, Germany, Italy, Japan, South Korea and Switzerland based on the results from the pre-planned futility analysis (PO) (NCT05151471)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top